Clinical Trial: BCG in Combination With Durvalumab in Adult BCG-naïve, High-risk NMIBC Participants
Study Status: Completed
Recruit Status: RECRUITING
Condition: Non-Muscle- Invasive Bladder Cancer
Study Type: INTERVENTIONAL
Official Title: A Phase IIIb Open-Label, Single-Arm, Multi-Center, US Study of Bacillus Calmette-Guerin (BCG) Administered in Combination With Durvalumab in Adult BCG-naïve, High-risk Non-Muscle- Invasive Bladder Can
Brief Summary:
The purpose of this study is to assess the safety, tolerability, and efficacy profile of durvalumab + BCG (induction and maintenance) combination therapy in adult United States participants with a histologically confirmed diagnosis of high-risk non-muscle-invasive bladder cancer (NMIBC), who have received no prior systemic therapy for NMIBC, and who are BCG-naïve.
Read more